AAA
SLNO

Affinity Asset Advisors’s Soleno Therapeutics SLNO Stock Holding History

Affinity Asset Advisors’s Portfolio SLNO Stock Details SLNO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-200
Closed -$8.99K – 111
2024
Q4 		$8.99K Buy
+200
New +$10.4K ﹤0.01% 84

Other funds holding SLNO

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Affinity Asset Advisors's SLNO Position: Q4 2025 in Review

Affinity Asset Advisors sold out of Soleno Therapeutics (SLNO) in Q4 2025, closing a stake of 200,000 shares — an estimated $13.5M sold.

Affinity Asset Advisors first reported a position in SLNO in Q3 2024 and held it in 4 quarters. The position peaked at $13.5M in Q3 2025. 247 funds tracked by Wall St. Rank hold SLNO as of Q4 2025.

  • Affinity Asset Advisors reported no remaining Soleno Therapeutics position as of Q4 2025 after selling out during the quarter.
  • Affinity Asset Advisors sold 200,000 Soleno Therapeutics shares in Q4 2025, an estimated $13.5M.
  • Affinity Asset Advisors first reported a position in Soleno Therapeutics in Q3 2024 and held it in 4 quarters.
  • Affinity Asset Advisors's Soleno Therapeutics position peaked at $13.5M in Q3 2025.
  • 247 funds tracked by Wall St. Rank held Soleno Therapeutics as of Q4 2025.

Based on Affinity Asset Advisors's 13F filing for Q4 2025, filed 13 Feb 2026.